A study to assess whether curcumin can maintain remission in Rheumatoid arthritis while tapering disease modifying anti- rheumatic drugs

INTERVENTION: Intervention1: Curcumin ‐ piperine tablet: Curcumin ‐ piperine tablet Dose ‐ 1gram twice daily for 12 months Control Intervention1: Placebo: 1 gram bd CONDITION: Rheumatoid arthritis PRIMARY OUTCOME: Number of flare and time to flare in placebo and curcumin arm will be compared‐‐‐‐‐‐Timepoint: 1 YEAR SECONDARY OUTCOME: 1.Cytokine levels ( MBDA assay: multibiomarkerdisease activity (MBDA) score ) which is a validated score of 12 cytokines will be done in patients who have flared and those who are in remission to see which are the cytokines suppressed by curcumin to maintain remission ; 2.Change in DAS 28 in placebo and curcumin arm ; 3.Change in HAQ DI in placebo and curcumin arm ; ‐‐‐‐‐‐Timepoint: 1 YEAR INCLUSION CRITERIA: Diagnosed cases of rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria On conventional DMARDs for at least last six months. On sustained remission based on DAS 28 (DAS 28 < 2.6) and SDAI â?¤ 3.3 and TJC (44) < 0 and SJC (44) < 0 for more than 6 months without requirement of corticosteroids or NSAIDs. Documented remission status at a minimum of two consecutive visits during last 6 months .